Matinas BioPharma Holdings, Inc. (MTNB)
$2.50-8.76%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $14M
- Beta
- 1.70
- P/E (TTM)
- -0.14
- Short % float
- 1.28%
- Days to cover
- 1.0
- SI change
- -87.3%
- 1W
- -16.94%
- 1M
- -13.19%
- vs SPY 1W
- -16.80%
- vs SPY 1M
- -15.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 24
- GROWTH
- 43
- GARP
- 6
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-108.9%
REV YoY-
ROE-181.5%
EPS YoY-
ROA-214.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.14
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.59
P/FCF-
EV/EBITDA-0.05
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.33
ALTMAN Z-
CURR RATIO0.85
ND/EBITDA-
BETA1.70
Company news
FAQ
- What is LOPJLB’s current signal on MTNB?
- LOPJLB’s latest quantitative signal on Matinas BioPharma Holdings, Inc. (MTNB) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is MTNB in?
- Matinas BioPharma Holdings, Inc. (MTNB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Matinas BioPharma Holdings, Inc. (MTNB) do?
- Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therap…